# Immunic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunic

- Industry: Biotechnology
- Headquarters: Munich, Germany
- Website: www.imux.com
- Total disclosed funding: $35M
- Latest round: Series A (Sep 5, 2017)
- Investors on record: 7

## About

Based in Munich, Germany, and founded in 2016, Immunic AG operates as a biotechnology that provides orally administered immunology therapies for patients. In January 2024, the firm raised USD 80 million in PIPE funding led by returning investor BVF Partners, with participation from other returning investors Adage Capital Management, L.P. and RTW Investments. Investors Avidity Partners Management Lp, Janus Henderson Investors, Soleus Capital, and other  investors also participated in the round. As of 2024, the company is headed by its CEO Dr. Daniel Vitt. The company bears the ticker symbol Nasdaq: IMUX.

Vidofludimus Calcium is a Immunic product, which helps solution for the treatment of autoimmune diseases. Vidofludimus Calcium is an oral treatment that aims to provide coeliac disease sufferers with a compliant way to manage their condition.

The company plans to use the January 2024 funding to further support the ongoing clinical development of its three-lead product.

## Funding rounds

- Series A, Sep 5, 2017, $12M — Omega Funds, Fund+
- Series A, Feb 1, 2017, $4.3M — BMP
- Series A, Jun 1, 2015, $19M — EQT Life Sciences, High-Tech Gruenderfonds, Bayern Kapital, LifeCare Partners

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A
- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Series A
- LifeCare Partners (https://capitalatlas.ai/funds/lifecare-partners) — Series A
- BMP (https://capitalatlas.ai/funds/bmp) — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A
- Fund+ (https://capitalatlas.ai/funds/fund) — Series A